128102-80-7

Basic information

• Product Name: 2-METHYL-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE
• Synonyms: 2-METHYL-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE
• CAS NO: 128102-80-7
• Molecular Formula: C₈H₇N₃O
• Molecular Weight: 161.16068
• EINECS: -0
• Mol File: 128102-80-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-METHYL-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-METHYL-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE(128102-80-7)
• EPA Substance Registry System: 2-METHYL-4H-PYRIDO[2,3-B]PYRAZIN-3-ONE(128102-80-7)

Safety Data

• Hazardous Substances Data: 128102-80-7(Hazardous Substances Data)

Upstream product

• 169692-47-1 2-ethoxycarbonylmethylene-1,2-dihydro-4H-pyrido<2,3-b>pyrazin-3-one 
• 54231-35-5 3-fuoro-2-nitropyridine 
• 165615-64-5 (R)-2-methyl-1,2-dihydropyrido[2,3-b]pyrazin-3(4H)-one 
• 856970-14-4 (7-bromo-3-oxo-3,4-dihydro-pyrido[2,3-b]pyrazin-2-yl)-acetic acid ethyl ester 
• 155629-95-1 7-bromo-2-methyl-4H-pyrido[2,3-b]pyrazin-3-one 
• 617-35-6 2-oxo-propionic acid ethyl ester 
• 452-58-4 2,3-Diaminopyridine 
• 127-17-3 2-oxo-propionic acid 
• 1825-45-2 2,2-dihydroxypropanoic acid 
• 169692-49-3 7-bromo-2-ethoxycarbonylmethylene-1,2-dihydro-4H-pyrido<2,3-b>pyrazin-3-one 
• 38875-53-5 5-bromo-pyridine-2,3-diamine 

Downstream Products

• 1613148-80-3 2-methyl-4-[2-(5-methyl-1-phenyl-1H-benzimidazol-2-yl)ethyl]pyrido[2,3-b]pyrazin-3(4H)-one 
• 1552287-69-0 C₁₉H₁₆ClN₅O₂ 
• 1552287-68-9 C₁₉H₁₆ClN₅O₂ 
• 1552286-92-6 C₁₉H₁₈ClN₅O₂ 
• 1552286-91-5 C₁₉H₁₆ClN₅O₂ 
• 1552286-86-8 C₂₁H₂₀ClN₅O₂ 
• 1552286-63-1 C₁₉H₁₈ClN₅O₂ 
• 1552286-61-9 C₁₈H₁₆ClN₅O₂ 
• 1552286-60-8 C₁₈H₁₆ClN₅O₂ 
• 1552286-59-5 C₁₇H₁₄ClN₅O₂ 
• 1552286-58-4 C₂₀H₂₀ClN₅O₂ 
• 1552286-57-3 C₁₈H₁₆ClN₅O₂ 
• 1552286-41-5 C₁₈H₁₄ClN₅O₃ 
• 1552286-23-3 C₂₁H₁₈ClN₅O₂ 

Relevant articles and documents

Diversity-Oriented Synthesis as a Strategy for Fragment Evolution against GSK3β

Traditional fragment-based drug discovery (FBDD) relies heavily on structural analysis of the hits bound to their targets. Herein, we present a complementary approach based on diversity-oriented synthesis (DOS). A DOS-based fragment collection was able to produce initial hit compounds against the target GSK3β, allow the systematic synthesis of related fragment analogues to explore fragment-level structure-activity relationship, and finally lead to the synthesis of a more potent compound.

Pyrido[4,3- e ][1,2,4]triazolo[4,3- a ]pyrazines as selective, brain penetrant phosphodiesterase 2 (PDE2) inhibitors

A novel series of pyrido[4,3-e][1,2,4]triazolo[4,3-a]pyrazines is reported as potent PDE2/PDE10 inhibitors with drug-like properties. Selectivity for PDE2 was obtained by introducing a linear, lipophilic moiety on the meta-position of the phenyl ring pending from the triazole. The SAR and protein flexibility were explored with free energy perturbation calculations. Rat pharmacokinetic data and in vivo receptor occupancy data are given for two representative compounds 6 and 12.

4-METHYL-2,3,5,9,9B-PENTAAZA-CYCLOPENTA[A]NAPHTHALENES

The invention relates to 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalene derivatives of general formula (I) which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.

4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes

The invention relates to 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalene derivatives of general formula (I) which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.

PYRIDINE COMPOUNDS AND USES THEREOF

The present invention is directed to pyridine compounds of Formula (I). Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds as therapeutic agents treating neurological and psych

Reaction Products of Dialkyl Acetylenedicarboxylates with 2,3-Diaminopyridine

The condensation of dialkyl acetylenedicarboxylates 1 and 2 with 2,3-diaminopyridine (3) or its 5-bromo derivative 4 in ethanol gave pyridopyrazinones with a common side chain -CH2COOR at their 2-position, 5-7, but in the presence of sulfuric acid the reaction afforded their isomers with the same side chain at the 3-position, 8-10.All of the products were shown to exist in enamine form, in which a ring double bond has been displaced onto their side chain (=CH-COOR) being facilitated by an internal chelation as demonstrated by their ir and 1H nmr spectra.

Unambiguously Confirmed Structure of 2-Phenacylidene-1,2-dihydro-4H-pyridopyrazin-3-one and 3-Phenacylidene-3,4-dihydro-1H-pyridopyrazin-2-one

To determine the structures of two isomeric products, 2-phenacylidene-1,2-dihydro-4H-pyridopyrazin-3-one (2) and 3-phenacylidene-3,4-dihydro-1H-pyridopyrazin-2-one (3) obtained by condensation of 2,3-diaminopyridine (1) with ethyl benzoylpyruvate , these compounds were hydrolyzed to give 2-methyl-4H-pyridopyrazin-3-one (4) and 3-methyl-1H-pyridopyrazin-2-one (5), respectively .Both hydrolysates 4 and 5 were hydrogenated to afford 2-methyl-1,2-dihydro-4H-pyridopyrazin-3-one (6) and 3-methyl-3,4-dihydro-1H-pyridopyrazin-2-one (7).The latter compound was identical with an unequivocally synthesized compound providing proof for the structures of all these compounds.

Comparative Kinetic Studies on the Synthesis of Quinoxalinone Derivatives and Pyridopyrazinone Derivatives by the Hinsberg Reaction

Kinetic studies on the anelation of quinoxalinone derivatives 3a-c and pyridopyrazinone derivatives 5a-c and 6a-c synthesized by the Hinsberg reaction is reported. o-Phenylenediamine or 2,3-diaminopyridine were treated with bifunctional carbonyl compounds such as glyoxylic, pyruvic and benzoylformic acids under different experimental conditions.When pyridopyrazine derivatives were synthesized both position isomers were achieved applying regioselective reactions.Mixture were avoided by looking for special experimental conditions that led unambigously to only one of the components of the classic "Hinsberg mixture".Quinoxalinone derivatives 3a-c were obtained at room temperature in good yields (>90percent) using anhydrous methanol or ethanol as solvents.On the other hand, only pyridopyrazin-3(4H)-one (5a) was regioselectively attained in aqueous buffer of pH 7 while 3-methylpyridopyrazinone derivatives were regioselectively separated using anhydrous methanol for one isomer, 5b, and anhydrous chloroform for the other isomer, 6b, at room temperature.Yields were higher than 80percent.Reactions with benzoylformic acid did not give good yields and only 2-phenylpyridopyrazin-3(4H)-one (5c) could be obtained using anhydrous chloroform (yield pyrazin-3(4H)-one (5c) in good yields applying this technique.The other isomer, 3-phenylpyrazin-2(1H)-one (6c) was always formed together with the former isomer and could not be isolated from the mixture, when other solvents than chloroform were used as the reaction media.